Skip to content

Intraoperative Small-dose Esketamine Infusion for Pain Control in Burn Patients

Intraoperative Small-dose Esketamine Infusion for Pain Control in Burn Patients

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04682782
Enrollment
26
Registered
2020-12-24
Start date
2020-07-14
Completion date
2020-12-30
Last updated
2020-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns

Brief summary

This study aim to determine whether a small-dose esketamine infusion can be used for pain control in severe burn patients, and thereby reduce the total intra-operative opioid requirement. Secondary objectives are to determine whether this low-dose esketamine infusion will increase the stability of circulation.

Interventions

DRUGEsketamine

Esketamine is infused through the whole period of surgery. Participants randomized to the esketamine arm will receive 1 mg/ml solution infused at 0.1 mg/kg/hour (0.1 ml/kg/h) .

DRUGSaline

Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the surgery.

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All intubated adult burn patients( age\>18 ), presenting to the operating room; * Burn area\> 30%.

Exclusion criteria

* Allergy to Esketamine or benzodiazepines * Esketamine or ketamine use in the preceding 24 hours * Increased intracranial pressure * Increased intraocular pressure * Porphyria * Thyroid disorders * Seizures * Acute myocardial ischemia * Children (patients under age 18), prisoners, pregnant or breastfeeding women, patients with psychosis, patients with developmental delay, and any condition which, in the opinion of the investigator, would prevent full participation in this study or would interfere with the evaluation of the trial endpoints.

Design outcomes

Primary

MeasureTime frameDescription
Intraoperative sufentanil24 hoursFor all participants, the dose of intraoperative sufentanil will be recorded in micrograms and compared between the two arms.

Secondary

MeasureTime frameDescription
Intraoperative blood pressure24 hoursFor all participants, blood pressure will be recorded and compared between the two arms.
Intraoperative heart rate24 hoursFor all participants, heart rate will be recorded and compared between the two arms.
Intraoperative cardiac index24 hoursFor all participants, cardiac index will be recorded and compared between the two arms.
Post-operative recovery time24 hoursFor all participants, the recovery time of spontaneous breathing will be recorded.

Countries

China

Contacts

Primary ContactQingyu SHI, MD
shiqinyu_001@zju.edu.cn+8613777564585

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026